Understanding HPLC Purity in Peptide Research: What the Numbers Mean

Reverse-phase HPLC (RP-HPLC) separates peptide components based on hydrophobicity using a C18 or C8 stationary phase and an acetonitrile/water gradient mobile phase. The UV detector (typically at 214 nm, which detects the peptide bond) generates a chromatogram showing peaks for the target peptide and any impurities.

Purity is reported as the area percentage of the target peak relative to the total peak area: Purity (%) = [Target peak area ÷ Total peak area] × 100. This is a relative measure — it tells you what fraction of the UV-absorbing material is the target compound, not the absolute mass of impurities present.

The most common impurities in synthetic peptides are: (1) Deletion sequences — peptides missing one or more amino acids due to incomplete coupling during SPPS. These are structurally similar to the target and can be difficult to separate. (2) Oxidized variants — methionine, cysteine, and tryptophan residues are susceptible to oxidation during synthesis or storage, producing +16 Da mass shifts. (3) TFA adducts — trifluoroacetate counterions from the cleavage step can remain associated with the peptide. (4) Truncated sequences — premature chain termination products.

A high-quality CoA will show a clean chromatogram with a single dominant peak and minimal baseline noise. Multiple peaks of comparable area indicate a poorly purified product that could compromise experimental results.

HPLC purity alone does not confirm molecular identity — a 99% pure peptide could theoretically be 99% pure wrong compound. Mass spectrometry (ESI-MS or MALDI-TOF) is essential for identity confirmation. The observed [M+H]⁺ or [M+2H]²⁺ ion should match the theoretical monoisotopic mass within ±0.5 Da (ESI) or ±1 Da (MALDI).

When reviewing a CoA, look for both the HPLC chromatogram and the mass spectrum. A reputable supplier will provide both. The mass spectrum should show a clean molecular ion with minimal adducts or fragmentation.

The ≥98% purity threshold is not arbitrary — it reflects the point at which impurity-driven confounds become statistically significant in most in vitro and in vivo assays. At 95% purity, 5% of the administered dose is unknown material that could have its own biological activity, receptor binding, or toxicity.

For dose-response studies, receptor binding assays, or any experiment where quantitative accuracy is critical, purity directly affects the reliability of your results. Vitalis Research Compounds maintains ≥99.4% purity across all catalog compounds, verified by third-party HPLC and confirmed by mass spectrometry.